FisherVista

Pershing Square USA, Ltd. and Pershing Square Inc. have closed their combined initial public offerings and private placement, generating $5 billion in gross proceeds for PSUS.

Delta Gold Technologies is featured in the debut episode of The Innovation Report Series, exploring the commercial potential of quantum technologies and their impact across industries.

Oregen Energy Corp. has appointed Philip Birch, a key figure in the Venus discovery, as strategic advisor to evaluate a potential investment in Namibia's offshore Block 2812Ab, adjacent to the major Venus find.

Oregen Energy Corp. has appointed petroleum geoscientist Philip Birch, who played a key role in the Venus discovery, as strategic advisor to evaluate an investment in Namibia’s offshore Block 2812Ab adjacent to the Venus find.

inCruises achieved its best Wave Season ever, booking over 50,000 passengers across 560 itineraries on 12 cruise lines, driven by strong international demand and program upgrades.

Twin Vee PowerCats Co. announced a 10% year-over-year revenue increase in the first quarter of 2026, its fourth consecutive quarter of growth, while advancing the relaunch of its Bahama Boat Works luxury brand.

The copper market is experiencing heightened volatility driven by geopolitical uncertainties rather than traditional supply-demand fundamentals, according to an ING analysis, with implications for mining companies and investors.

Datavault AI highlights its distributed edge computing strategy ahead of U.S. Senate markup of the Digital Asset Market Clarity Act, expecting regulatory clarity to boost demand for secure data processing and AI infrastructure.

MindBio Therapeutics Corp. announced the development of AI-powered fatigue recognition technology that analyzes voice patterns, to be added as a commercial feature to its Edge AI Intoxication Detection Kiosks, targeting high-risk industries like aviation, road transport, and mining.

HeartBeam initiated a pilot study for its investigational patch-based 12-lead ECG device aimed at detecting ischemia, targeting a $2 billion market and expanding ambulatory cardiac monitoring beyond rhythm assessment.

Nightfood Holdings Inc. announced a strategic partnership initiative with ToDo Robotics to accelerate the deployment of its AI-powered automation platform across hospitality, healthcare, and foodservice sectors.

Planet Ventures Inc. has invested USD$100,000 in Lux Aeterna, a startup developing the world's first fully reusable satellite platform, aiming to revolutionize space infrastructure with satellite recovery and relaunch capabilities.

Following an Andes hantavirus incident aboard a cruise ship, NanoViricides underscores the potential need for broad-spectrum antiviral treatments, pointing to its clinical-stage drug candidate NV-387 as a possible therapeutic platform for emerging viral threats.

Kairos Pharma announced its virtual annual meeting and disclosed a going concern notice in its 2025 annual report, highlighting financial uncertainty for the clinical-stage biopharmaceutical company.

Shareholders of Wheaton Precious Metals Corp. elected all nominated directors and approved executive compensation with 95.16% support, while Randy V.J. Smallwood transitions to non-executive chair as part of a leadership transition.

Oncotelic Therapeutics is advancing its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting Alzheimer's disease and biodefense, amid a broader industry push for scalable CNS delivery technologies.

SPARC AI Inc. is developing a software-only system for GPS-denied navigation and precision targeting in drones, addressing a critical gap as defense agencies prioritize scalable autonomous systems.

MindBio Therapeutics is advancing an AI-driven voice analysis platform to detect drug and alcohol intoxication in real time, targeting growing markets in workplace safety, healthcare, and public safety.

SureNano Science Ltd., through GlucaPharm Inc., is progressing its patented triple agonist peptide GEP-44 for obesity and metabolic diseases, aiming to compete in a market projected to exceed $200 billion.